Gait-speed and oxygen flow during six-minute walk test predicts mortality in patients with advanced lung disease.


Journal

Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace
ISSN: 1122-0643
Titre abrégé: Monaldi Arch Chest Dis
Pays: Italy
ID NLM: 9307314

Informations de publication

Date de publication:
12 Feb 2020
Historique:
received: 15 10 2019
accepted: 21 01 2020
entrez: 20 2 2020
pubmed: 20 2 2020
medline: 18 11 2020
Statut: epublish

Résumé

The six-minute walk test (6MWT) is a useful tool to predict outcomes in patients with advanced lung diseases. Greater distance walked has been shown to have more favorable prognostic value compared to other recorded variables.  We reviewed the medical records of 164 patients with advanced lung disease who underwent lung transplant evaluation. Results of the 6MWT (distance walked, oxygen required, and mean gait speed) were recorded and analyzed with respect to mortality. 6MWT mean oxygen (O2) flow via nasal cannula was 3.5 ± 3.7 L/min. The distance walked in meters (m) and % predicted were inversely associated with mortality, OR: 0.995 (0.992-0.998) and 0.970 (0.950-0.990), respectively. Patients who walked < 200 meters (OR: 2.1 (1.1-4.0)) or < 45% of predicted, OR: 2.7 (1.2-5.7) had higher mortality. O2 flow during the test had a direct association with mortality (OR: 1.1 (1.0-1.2). In multivariate analysis, O2 flow > 3.5 L/min remained predictive of mortality, OR: 1.1 (1.0-1.2). Mean gait speed was higher in patient who lived compared with patients who died (mean 0.83 ± 0.35 m/mim vs mean 0.69 ± 0.33 m/min, respectively, p= 0.03). Gait speed was a predictor of survival, OR 3.4 (1.1, 10.6). O2 flow during the 6MWT was an independent predictor of mortality in patients with advanced lung disease. The patients that required more than 3.5 L/m of O2 had a higher mortality. Faster gait speed during the 6MWT was also associated with better survival.

Identifiants

pubmed: 32072801
doi: 10.4081/monaldi.2020.1186
pmc: PMC7905842
mid: NIHMS1666014
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIA NIH HHS
ID : T32 AG000262
Pays : United States

Références

Ann Am Thorac Soc. 2018 Jan;15(1):3-10
pubmed: 28933948
J Cardiopulm Rehabil. 2004 Jul-Aug;24(4):274-80
pubmed: 15286536
J Heart Lung Transplant. 1997 Mar;16(3):313-9
pubmed: 9087875
Chest. 2006 Mar;129(3):746-52
pubmed: 16537877
Can Respir J. 2015 Jul-Aug;22(4):225-9
pubmed: 26252533
Respir Med. 2013 Dec;107(12):1881-7
pubmed: 24157200
Am J Respir Crit Care Med. 2015 Oct 1;192(7):843-52
pubmed: 26067395
Eur Respir J. 2004 Jan;23(1):28-33
pubmed: 14738227
J Heart Lung Transplant. 2016 Apr;35(4):433-9
pubmed: 26922274
Chest. 2003 Sep;124(3):922-8
pubmed: 12970018
Am J Transplant. 2006;6(5 Pt 2):1212-27
pubmed: 16613597
Am J Respir Crit Care Med. 2006 Jun 15;173(12):1326-34
pubmed: 16543549
N Engl J Med. 2003 Feb 20;348(8):683-93
pubmed: 12594312
Ann Thorac Med. 2011 Jul;6(3):141-6
pubmed: 21760846
Respir Care. 2013 Dec;58(12):2113-9
pubmed: 23696689
Eur Respir J. 2013 Aug;42(2):333-40
pubmed: 23222875
Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7
pubmed: 12091180
J Thorac Dis. 2017 Aug;9(8):2670-2674
pubmed: 28932574
Am J Transplant. 2017 Jan;17 Suppl 1:357-424
pubmed: 28052607
Anatol J Cardiol. 2015 Mar;15(3):249-54
pubmed: 25880178
J Cardiopulm Rehabil Prev. 2010 May-Jun;30(3):195-202
pubmed: 20040883
Eur Respir J. 2001 Apr;17(4):647-52
pubmed: 11401059
JAMA. 2011 Jan 5;305(1):50-8
pubmed: 21205966
Am J Respir Crit Care Med. 2006 Sep 15;174(6):659-64
pubmed: 16778159
Br Med J (Clin Res Ed). 1982 May 29;284(6329):1607-8
pubmed: 6805625

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH